U.S. Markets close in 8 mins.

iCo Therapeutics Inc. (ICO.V)

TSXV - TSXV Delayed Price. Currency in CAD
Add to watchlist
0.0450.000 (0.000%)
As of 3:05PM EDT. Market open.
People also watch
KNE.VATE.VDMA.VBTI.VEKG.V
Full screen
Previous Close0.045
Open0.040
Bid0.040 x 0
Ask0.045 x 0
Day's Range0.040 - 0.045
52 Week Range0.030 - 0.090
Volume199,000
Avg. Volume263,509
Market Cap3.8M
Beta3.70
PE Ratio (TTM)-3.75
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile12 days ago

    iCo Therapeutics Inc. Approves Advance Notice Policy

    Vancouver, British Columbia--(Newsfile Corp. - August 4, 2017) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") today announced that its board of directors has adopted an advance notice policy (the "Advance Notice Policy").The purpose of the Advance Notice Policy is to provide shareholders, directors and management of the Company with direction on the procedure for shareholder nomination of directors. The Advance Notice Policy is the framework by which the Company seeks to ...

  • Newsfile2 months ago

    iCo Therapeutics Announces Election of Directors

    Vancouver, British Columbia--(Newsfile Corp. - June 30, 2017) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), today announced the election of directors at the annual meeting of shareholders held on June 29, 2017. At the annual meeting of shareholders held on June 29, 2017, Andrew Rae, Susan Koppy, Wiiliam Jarosz and Michael Liggett were elected directors of the Company and will hold office until the next annual general meeting ...

  • Newsfile2 months ago

    iCo Therapeutics Announces Pre IND meeting for Novel Glaucoma Asset

    Vancouver, British Columbia--(Newsfile Corp. - June 15, 2017) - iCo Therapeutics (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), today reported it will hold a pre IND meeting with the Division of Transplantation and Ophthalmology, US Food and Drug Administration (FDA) on June 21st, 2017. Discussions will focus on a proprietary dual action glaucoma asset with a novel mechanism of action that reduces intraocular pressure (IOP). The target is validated by literature and a ...